Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. This patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
The granted patent is a significant milestone for Greenland Mines, as it provides robust protection for the Klotho gene therapy platform in Australia, a key market for biotechnology innovation. The patent covers a broad range of technologies, including gene therapy constructs and delivery systems, which are critical for advancing the company’s therapeutic programs. By securing this intellectual property, Greenland Mines enhances its competitive position in the neuromuscular disease treatment landscape, particularly for ALS, a devastating condition with limited treatment options.
The KLTO-202 program, which focuses on ALS, aims to leverage the neuroprotective properties of the Klotho protein. Klotho is known for its role in aging and neuroprotection, and its expression through gene therapy could potentially slow or halt disease progression. The Australian patent adds to the company’s growing portfolio of intellectual property, which is essential for attracting partners and investors. The full press release can be viewed at https://nnw.fm/PVbbH.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For investors, the patent grant underscores the company’s commitment to advancing its biotech division alongside its mining operations. The latest news and updates relating to GRML are available in the company’s newsroom at https://nnw.fm/GRML. This development highlights the potential for gene therapy to address unmet medical needs, and Greenland Mines is positioning itself at the forefront of this innovation.
